Processa Pharmaceuticals, Inc. Long-term Line of Credit
Processa Pharmaceuticals, Inc. (PCSA) had Long-term Line of Credit of $229.98 thousand as of 2017-06-30, per its 10-Q filed 2017-10-04.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:LineOfCredit · last filed 2017-11-20
- 2017-06-30: Long-term Line of Credit $229.98K.
- 2017-03-31: Long-term Line of Credit $229.98K.
- 2016-12-31: Long-term Line of Credit $229.98K.
- 2016-09-30: Long-term Line of Credit $229.98K.
| Period end | Long-term Line of Credit |
|---|---|
| 2017-06-30 | $229.98K 10-Q · filed 2017-10-04 |
| 2017-03-31 | $229.98K 10-Q · filed 2017-10-04 |
| 2016-12-31 | $229.98K 10-Q · filed 2017-11-20 |
| 2016-09-30 | $229.98K 10-Q · filed 2017-09-08 |
| 2016-06-30 | $229.98K 10-Q · filed 2017-08-30 |
| 2015-09-30 | $229.98K 10-Q · filed 2015-12-01 |
| 2015-06-30 | $229.98K 10-Q · filed 2015-08-19 |
| 2015-03-31 | $229.98K 10-Q · filed 2015-05-15 |
| 2014-12-31 | $229.98K 10-Q · filed 2015-12-01 |
| 2014-09-30 | $229.98K 10-Q · filed 2014-11-13 |
| 2014-06-30 | $229.98K 10-Q · filed 2014-08-19 |
| 2014-03-31 | $229.98K 10-Q · filed 2014-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |